Caring Closures International & its Safe Rx® Pharmacy Innovations
Caring Closures International LLC is a social impact company poised to replace a broad cross section of the global child-resistant packaging market. The Company has initially deployed its technology where the social need is most urgent, and the customer and impact ROI is the highest. Specifically, it is picking up where DEA security lapses in the pharmacy sector.
The DEA regulates controlled substance security throughout the supply chain, but its authority and oversight end at the pharmacy counter, with a significant consequence: 75% of post-pharmacy drug diversion is traceable to uncontrolled access to medication. This lapse in security after the pharmacy has had serious cascade effects in public health, with 70% of teen drug misuse sourced from home medicine cabinets, 60% higher overdose probabilities in homes with opioids, and other far-reaching negative consequences. Caring Closures’ wholly owned subsidiary Safe Rx sells the nation’s first locking prescription vial (LPV®) designed specifically for pharmacy medication dispensing of opioids, stimulants, and benzodiazepines (OSBs), the three most misused controlled substances, representing over 300 million prescriptions annually in the United States.
The Company’s Safe Rx® LPV® is a 4-digit PIN-secured prescription vial with 10,000 possible combinations, tamper-evident features, and a certified senior-friendly design. The patient’s preferred combination code is set at the pharmacy during the fill process, and the patient receives a filled locked vial at pickup. The product integrates natively into e-prescribing and pharmacy billing workflows and has earned a Model Practice Designation from a leading national public health organization. The Company holds 15 issued patents with three pending, covering the locking mechanism, pharmacy manual and robotic PIN encoding, and a new medication adherence pharmacy SaaS solution. Safe Rx® LPV®s carry a manufacturing and workflow cost advantage of more than 16x the nearest consumer-grade alternative, making it the only solution viable at pharmacy dispensing scale. Clinical study results include 100% reductions in missing medication, 100% of household members reporting difficulty stealing pills, and a 3.8x increase in patient awareness of medication risks. The LPV® also reduces the top three barriers to patient enrollment in medication-assisted treatment, the gold standard for opioid addiction treatment currently accessible by only 22% of opioid recovery patients in the US.
Safe Rx has built rapid commercial traction across multiple segments, with a customer base exceeding 350 customers. Selected customer programs include a federal agency-wide program, 3 statewide opioid programs, a self-insured employer program with a state chamber of commerce, and others. Its recent transition to enterprise segments, with larger deal sizes and longer contract terms, has created an inflection point for growth and initial momentum towards insurance reimbursement to pharmacies for LPV® dispensing. At scale, LPV® dispensing of OSBs is projected to prevent ~1 million substance use disorders while saving $236 billion in excess costs of care over a ten-year period.
The Company’s roadmap Pediatric LPV® applies the same patented locking mechanism in a 100-combination locking vial designed for dispensing of pediatric fatality risk medications representing approximately 40%-50% of total U.S. prescription volume. At scale, Pediatric LPV® dispensing, together with OTC licensing of the Company’s closure technology, is projected to prevent 5 million child poisonings and save $3.3 billion in annual treatment costs over a ten-year period.
Safe Rx is also extending its pharmacy leadership into medication adherence, one of the most persistent and costly problems in healthcare. The Company has engineered a detethered drop-in sensor that transforms any prescription vial or pill organizer into a smart, connected remote monitoring device, detecting patient dosing events and transmitting adherence data in real time to caregivers, pharmacies and prescribers. Its detethered solution reaches approximately 2x the eligible patient market of competing solutions at 1/20th the hardware cost per patient, without any impact to pharmacy workflow and near frictionless patient enrollment. The device enables pharmacy billing of $94 per patient per month at a 58% margin, and positive feedback loops between its adherence and LPV® lines are expected to accelerate LPV® pharmacy reimbursement and the pace of LPV® dispensing adoption.
But its progress in the pharmacy sector with Safe Rx is expected to open a much more expansive opportunity in global packaging markets. Caring Closures, the parent company of Safe Rx, maintains full ownership of its core patent portfolio, covering packaging fields of use globally with protection extending into the 2040’s, with a global potential licensing market representing more than 130 billion units annually. Applicable segments include international prescription vials, global OTC and other product categories with high rates of pediatric poisoning or heightened risk, e.g. detergent pods, liquid nicotine and others. With its initial progress in the US pharmacy sector and anticipated growth over the next 5-10 years, the Company is creating a pathway to fulfill its ultimate vision: a world free of addictions and pediatric poisonings caused by uncontrolled access to prescription medication and consumer products.
For more information on the Company and its solutions, please contact Milton Cohen at mcohen@safe-rx.com or visit safe-rx.com.